GI Colorectal / Rectal Cancer (CRC)

**Non-Intervention CRC**
- Localized
- Colon
- Rectal
- Adjuvant
  - Colon
  - Rectal
- Neoadjuvant / Adjuvant
  - Colon
  - Rectal

**Metastatic CRC**
- Colorectal
- Rectal
- Anal
- **Beyond 3rd Line HER2+**

**1st Line**
- Colon
- IRB# 21658 BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
- Rectal
- IRB# 18000 EXERCISING TOGETHER for Couples Coping with CRC

**2nd Line**
- Colon
- IRB# 21819 A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
- Rectal
- IRB# 20980 Immunotherapy during neoadjuvant therapy for rectal cancer, a phase II randomized multi-center trial with and without APX005M, an anti-CD40 agonist

**3rd Line**
- Colon
- IRB# 21972 A Phase 3 Study to Evaluate the Efficacy and Safety of Olaparib Alone or In Combination With Bevacizumab Compared To Bevacizumab With 5-Fu In Participants With Unresectable Or Metastatic Colorectal Cancer Who Have Not Progressed Following First-Line Induction Of FOLFOX With Bevacizumab
- Rectal
- IRB# 21972 A Phase 3 Study to Evaluate the Efficacy and Safety of Olaparib Alone or In Combination With Bevacizumab Compared To Bevacizumab With 5-Fu In Participants With Unresectable Or Metastatic Colorectal Cancer Who Have Not Progressed Following First-Line Induction Of FOLFOX With Bevacizumab

**Adjuvant**
- Colon
- No Trials Currently Available

**Neoadjuvant**
- Colon
- IRB# 19576 Phase 1B Study to Assess the Safety of Neoadjuvant TAS-102 (Lonsurf) with Concurrent Radiation in Previously Untreated Resectable Stage II and Stage III Rectal Cancer
- Rectal
- IRB# 22447 Establishing a ctDNA biomarker to improve organ preserving strategies in patients with rectal cancer
- IRB# 22465 A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

**Metastatic Anal**
- IRB# 21819 A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer

**CROSS-DISEASE TRIALS:**
- IRB# TBD EAY131 (MATCH)

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php